Literature DB >> 23055893

Optimum Use of Therapeutic Drug Monitoring and Pharmacokinetics-Pharmacodynamics in the NICU.

Peter Gal1.   

Abstract

Therapeutic drug monitoring is increasingly giving way to dosing drugs based on population-based pharmacokinetic parameters, even when pharmacokinetic values vary quite a bit in individual patients. Further, drug concentrations are often considered appropriate if they are within a defined therapeutic range, even if the patient response is suboptimal. This lecture discusses the limitations of therapeutic ranges in neonates, and proposes greater emphasis on pharmacodynamic curves to individualize drug therapy. Examples are provided using methylxanthines, indomethacin, antiepileptic drugs and aminoglycosides. The potential to use pharmacokinetic findings to describe physiologic changes and occasionally assist with diagnosis is also discussed.

Entities:  

Keywords:  neonate; pharmacodynamics; pharmacokinetics; therapeutic monitoring

Year:  2009        PMID: 23055893      PMCID: PMC3461980          DOI: 10.5863/1551-6776-14.2.66

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  36 in total

1.  Treatment of seizures in newborns: the dilemma of starting the right drug, at the right time, in the right doses, and monitoring the right endpoints.

Authors:  Peter Gal; J Laurence Ransom
Journal:  J Pediatr Pharmacol Ther       Date:  2005-01

2.  Indomethacin for patent ductus arteriosus closure. Application of serum concentrations and pharmacodynamics to improve response.

Authors:  P Gal; J L Ransom; S Schall; R L Weaver; A Bird; Y Brown
Journal:  J Perinatol       Date:  1990-03       Impact factor: 2.521

3.  Rapid sequential phenobarbital treatment of neonatal seizures.

Authors:  J T Gilman; P Gal; M S Duchowny; R L Weaver; J L Ransom
Journal:  Pediatrics       Date:  1989-05       Impact factor: 7.124

4.  Oral theophylline and diuretics improve pulmonary mechanics in infants with bronchopulmonary dysplasia.

Authors:  L C Kao; D J Durand; B L Phillips; B G Nickerson
Journal:  J Pediatr       Date:  1987-09       Impact factor: 4.406

5.  Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise?

Authors:  Girija Natarajan; Mirjana-Lulic Botica; Ronald Thomas; Jacob V Aranda
Journal:  Pediatrics       Date:  2007-05       Impact factor: 7.124

6.  A simple method for the estimation of glomerular filtration rate by gentamicin pharmacokinetics during routine drug monitoring in the newborn.

Authors:  G Koren; A James; M Perlman
Journal:  Clin Pharmacol Ther       Date:  1985-12       Impact factor: 6.875

7.  The dose response of theophylline in the treatment of apnea of prematurity.

Authors:  S C Muttitt; A J Tierney; N N Finer
Journal:  J Pediatr       Date:  1988-01       Impact factor: 4.406

Review 8.  Antibiotic resistance--what's dosing got to do with it?

Authors:  Jason A Roberts; Peter Kruger; David L Paterson; Jeffrey Lipman
Journal:  Crit Care Med       Date:  2008-08       Impact factor: 7.598

9.  Inadequacy of FDA dosing guidelines for theophylline use in neonates.

Authors:  J T Gilman; P Gal
Journal:  Drug Intell Clin Pharm       Date:  1986-06

10.  Gentamicin in neonates: the need for loading doses.

Authors:  P Gal; J L Ransom; R L Weaver
Journal:  Am J Perinatol       Date:  1990-07       Impact factor: 1.862

View more
  5 in total

1.  The History of PPAG: The First 30 Years.

Authors:  Robert L Poole
Journal:  J Pediatr Pharmacol Ther       Date:  2010-04

2.  Reply to: 'Is the use of prophylactic theophylline safe for the prevention of severe renal dysfunction in term and post-term neonates with perinatal asphyxia?'.

Authors:  H Al-Wassia
Journal:  J Perinatol       Date:  2014-01       Impact factor: 2.521

3.  Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin.

Authors:  J E Constance; D Reith; R M Ward; A Balch; C Stockmann; E K Korgenski; E A Thorell; C M T Sherwin
Journal:  J Perinatol       Date:  2017-06-08       Impact factor: 2.521

4.  Indomethacin pharmacodynamics are altered by surfactant: a possible challenge to current indomethacin dosing guidelines created before surfactant availability.

Authors:  Christopher McPherson; Peter Gal; J Laurence Ransom; Rita Q Carlos; Mary Ann V T Dimaguila; McCrae Smith; Christie Davonzo; John E Wimmer
Journal:  Pediatr Cardiol       Date:  2010-01-10       Impact factor: 1.655

5.  Incorporating pharmacodynamic considerations into caffeine therapeutic drug monitoring in preterm neonates.

Authors:  Tian Yu; Alfred H Balch; Robert M Ward; E Kent Korgenski; Catherine M T Sherwin
Journal:  BMC Pharmacol Toxicol       Date:  2016-06-07       Impact factor: 2.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.